PSMB1 proteasome 20S subunit beta 1
ENSG00000008018 · protein coding · Open Targets profile
Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). {ECO:0000269|PubMed:15244466, ECO:0000269|PubMed:27176742, ECO:0000269|PubMed:8610016}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Druggable Family
- Antibody
- GO CC high conf
- PROTAC
- Database Ubiquitination, Half-life Data, Small Molecule Binder
gnomAD loss of function constraint: o/e 0.27592000365257263 (upper bound 0.5182600021362305). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 210 registry trials, updated in the last three years, of the most advanced drugs against PSMB1 (ixazomib, bortezomib d-mannitol, carfilzomib, marizomib, oprozomib), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Andrzej JakubowiakUniversity of Chicago Comprehensive Cancer Center · 6 of 7 trials Phase 2+Ph2NCT01816971 · Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myelomabrief
- Shaji KumarECOG-ACRIN Cancer Research Group · 5 of 6 trials Phase 2+Ph3NCT01863550 · Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myelomabrief
- Bristol-Myers SquibbBristol-Myers Squibb · 4 of 4 trials Phase 2+Ph3NCT03651128 · Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)brief
- Philippe MOREAUNantes University Hospital · 3 of 3 trials Phase 2+Ph2NCT01936532 · Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)brief
- Shebli AtrashWake Forest University Health Sciences · 3 of 3 trials Phase 2+
- Jens HillengassRoswell Park Comprehensive Cancer Center · 2 of 3 trials Phase 2+Ph2NCT06627751 · Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Diseasebrief
- Ajay NookaEmory University · 2 of 2 trials Phase 2+
- Benjamin DermanUniversity of Chicago · 2 of 2 trials Phase 2+
- Manisha BhutaniWake Forest University Health Sciences · 2 of 2 trials Phase 2+
- Michel AttalCHRU - Hôpital Purpan Toulouse · 2 of 2 trials Phase 2+
- Neha KordeMemorial Sloan Kettering Cancer Center · 2 of 2 trials Phase 2+
- Noa BiranHackensack Meridian Health · 2 of 2 trials Phase 2+
- Shaji K. KumarMayo Clinic in Rochester · 2 of 2 trials Phase 2+
- Yael CohenTel-Aviv Sourasky Medical Center · 1 of 2 trials Phase 2+
- Ajay K. GopalFred Hutch/University of Washington Cancer Consortium · 1 of 1 trials Phase 2+
Registry trials of ixazomib, bortezomib d-mannitol, carfilzomib, marizomib, oprozomib updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 147 of 207 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 3 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
87 trials of drugs against PSMB1 were stopped early; 7 give no reason
Terminated, withdrawn and suspended interventional trials of ixazomib, bortezomib d-mannitol, carfilzomib, marizomib, oprozomib, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 87.
- terminated · 2026-09-29 · Hoffmann-La Roche · Carfilzomib“The study was terminated prematurely because the Sponsor decided not to pursue the development of forimtamig.”
- suspended · 2026-07-13 · Hackensack Meridian Health · Carfilzomib“Temporary Hold Pending Amendment Approval”
- terminated · 2026-06-30 · Alliance for Clinical Trials in Oncology · ixazomib“DSMB recommendation due to slow accrual”
- withdrawn · 2026-05-15 · Roswell Park Cancer Institute · Carfilzomib“Sponsor withdrawal of supplying investigational drug”
- terminated · 2026-05-13 · University Hospital, Caen · Ixazomib and Daratumumab“Early termination (regarding the follow-up of the patients). The required sample size was reached, and the primary endpoint was met.”
- terminated · 2026-05-06 · University of Michigan Rogel Cancer Center · Ixazomib“Lack of accrual”
- terminated · 2026-05-05 · Mayo Clinic · Ixazomib Citrate“Discontinued after interim analysis for futility; no treatment successes observed in the first 12 patients”
- terminated · 2026-05-04 · Takeda · Ixazomib“All participants on the study have concluded treatment, core study activities are complete, and the scientific goals of the study have been met.”
- terminated · 2026-02-10 · National Cancer Institute (NCI) · Carfilzomib“Inadequate accrual rate”
- terminated · 2026-01-29 · Teva Branded Pharmaceutical Products R&D LLC · Carfilzomib“Due to strategic reasons (no safety concerns).”
- terminated · 2026-01-05 · Universitätsklinikum Hamburg-Eppendorf · carfilzomib/lenalidomide/dexamethasone (KRD), ixazomib/lenalidomide/dexamethasone (IRD), carfilzomib/daratumumab/dexamethasone (KDD), isatuximab/carfilzomib/dexamethasone (Isa-KD)“The reason for the end of recruitment is that the recruitment target could not be achieved despite all efforts and the G-BA (financing party) does not consider a continuation of the AlloRelapseMM study to be expedient.”
- terminated · 2025-10-21 · University of California, San Diego · Ixazomib“The trial met its primary endpoint.”
- terminated · 2025-10-07 · University of Pennsylvania · matched by the registry's drug synonyms“Slow accrual at the time when sufficient participants were already enrolled to answer the scientific question posed by the study.”
- terminated · 2025-09-02 · Millennium Pharmaceuticals, Inc. · IXAZOMIB“Sponsor's decision”
- terminated · 2025-05-26 · Mayo Clinic · Carfilzomib“funding - sponsor filing Chapter 11 bankruptcy”
- terminated · 2025-05-02 · Gilead Sciences · Carfilzomib“This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.”
- terminated · 2025-04-20 · M.D. Anderson Cancer Center · Ixazomib, Ixazomib Citrate“Administratively Complete 75%<Participants”
- terminated · 2025-04-06 · Michael M. Pham · Ixazomib“Low enrollment”
- terminated · 2025-03-30 · Janssen Research & Development, LLC · Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2“The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee recommendation was early stop of the study for futility.”
- terminated · 2025-03-04 · Roswell Park Cancer Institute · Ixazomib Citrate“funding ended”
- terminated · 2025-02-19 · Intergroupe Francophone du Myelome · Ixazomib/Pomalidomide/Dexamethasone“Recruitment issue, 26 patients enrolled instead of 70 initially planned”
- withdrawn · 2024-11-19 · Kathleen Dorritie · Ixazomib“Closure of trial per BMS”
- terminated · 2024-09-19 · Suzanne Lentzsch, MD · Carfilzomib“Slow accrual and loss of funding”
- terminated · 2024-09-03 · Pfizer · Carfilzomib“A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.”
- withdrawn · 2024-07-16 · Dana-Farber Cancer Institute · Marizomib“Study support withdrawn”
Paediatric incentives and obligations for PSMB1's drugs
For ixazomib, bortezomib d-mannitol, carfilzomib, marizomib, oprozomib: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · PSMB1 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001806-PIP04-19-M02 (carfilzomib, Treatment of acute lymphoblastic leukaemia): PM: decision on the application for modification of an agreed PIP, 27 Oct 2023; EMA/PE/0000225846 (Ixazomib, Treatment of lymphoid malignancies (excluding multiple myeloma);Treatment of Multiple Myeloma): PM: decision on the application for modification of an agreed PIP, 14 Apr 2025; EMEA-002452-PIP01-18 (Marizomib, Treatment of malignant glial tumours): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 4 Dec 2019; EMEA-001806-PIP03-18 (carfilzomib, Treatment of Multiple Myeloma): W: decision granting a waiver in all age groups for all conditions or indications, 15 May 2019; +1 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/08/548 expired 3 Jun 2008: Treatment of multiple myeloma; EU/3/12/1060 withdrawn 8 Nov 2012: Treatment of systemic light chain amyloidosis; EU/3/11/899 positive 27 Sept 2011: Treatment of multiple myeloma; EU/3/18/2119 positive 14 Dec 2018: Treatment of glioma; +1 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Ninlaro: authorised since 21 Nov 2016, orphan medicine; Kyprolis: authorised since 19 Nov 2015Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of ixazomib, bortezomib d-mannitol, carfilzomib, marizomib, oprozomibRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 13 interventional studies of ixazomib, bortezomib d-mannitol, carfilzomib, marizomib, oprozomib include patients under 18; 3 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 7 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.